Compare BigBearai Holdings Inc (BBAI) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BigBearai Holdings Inc vs Summit Therapeutics Inc — how do they compare? BigBearai Holdings Inc trades at $3.27 (market cap $1.60B), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: Summit Therapeutics Inc is far larger — about 7.5× BigBearai Holdings Inc's market cap. Which is the better fit depends on your goals.
| BBAI | SMMT | |
|---|---|---|
Market Cap | $1.60B | $12.06B |
Sector | Technology | Health |
52-Week High | $8.91 | $26.98 |
52-Week Low | $2.61 | $12.55 |
Enterprise Value | $1.30B | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBAI trades at $3.26, up 0.93% with a bullish technical signal despite mixed earnings. The company reported Q2 2026 revenue growth of 13% but missed EPS expectations, continuing negative profitability trends. Recent news highlights defense contract wins and generative AI platform expansion, while analyst consensus remains cautious with 75% hold ratings.
The outlook remains challenging with persistent losses and negative cash flow projections for 2026. Investment opportunity lies in defense AI specialization and backlog growth, but risks include execution challenges, high valuation multiples, and dependence on government contracts. The stock requires careful monitoring of profitability improvements.
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BigBearai Holdings Inc
BigBearai Holdings Inc is a specialized provider of AI-driven decision intelligence solutions, primarily serving the U.S. defense, intelligence, and national security communities. It operationalizes complex data into actionable insights through its core modules—Observe, Orient, and Dominate—to support mission-critical operations and logistics.
Read more on BBAI →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
